Top-News
Biotechnologie USA

Savara News

Aktie
WKN:  A2DQ2B ISIN:  US8051111016 US-Symbol:  SVRA
4,04 €
+0,16 €
+4,12%
09.09.24
Handeln Depot/Watchlist
Aktienanzahl *
135,34 Mio.
Marktkapitalisierung *
525,23 Mio. €
Streubesitz
2,32%
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 27.11.2023

Savara News

08.09.24 - Businesswire
Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that new data from the Phase 3 ...
06.09.24 - Businesswire
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee.
03.09.24 - Businesswire
Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will ...
16.08.24 - Businesswire
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee.
15.08.24 - Businesswire
Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of an abstract for ...
12.08.24 - Businesswire
Savara Reports Second Quarter 2024 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second quarter ...
28.06.24 - Businesswire
Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of ...
26.06.24 - Businesswire
Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced positive results from the pivotal, ...
26.06.24 - Businesswire
Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it will host a conference call ...
17.03.21 - PR Newswire
Thinking about buying stock in FSD Pharma, Onconova Therapeutics, Nabriva Therapeutics, Zosano Pharma, or Savara?
Thinking about buying stock in FSD Pharma, Onconova Therapeutics, Nabriva Therapeutics, Zosano Pharma, or Savara? PR Newswire
16.03.21 - PR Newswire
Thinking about buying stock in Can Fite, Zomedica, AMC Entertainment, Savara, or SunLink Health?
Thinking about buying stock in Can Fite, Zomedica, AMC Entertainment, Savara, or SunLink Health? PR Newswire
11.07.17 - PR Newswire
Positive Interim Results Of Aironite Phase 2 Study Presented At 4th Annual Drug Discovery And Development Symposium For Pulmonary Hypertension
Positive Interim Results Of Aironite Phase 2 Study Presented At 4th Annual Drug Discovery And Development Symposium For Pulmonary Hypertension Aironite Significantly Lowered ...
20.06.17 - PR Newswire
Savara Set To Join Russell Microcap® Index
Savara Set To Join Russell Microcap® Index PR Newswire
05.06.17 - PR Newswire
Savara To Present At The Jefferies 2017 Global Healthcare Conference On June 9th
Savara To Present At The Jefferies 2017 Global Healthcare Conference On June 9th PR Newswire
02.06.17 - PR Newswire
Savara Announces Pricing Of Public Offering Of Common Stock
Savara Announces Pricing Of Public Offering Of Common Stock PR Newswire
01.06.17 - PR Newswire
Savara Announces Proposed Public Offering Of Common Stock
Savara Announces Proposed Public Offering Of Common Stock PR Newswire
10.05.17 - PR Newswire
Savara Announces Expedited U.S. Molgradex Development Strategy
Savara Announces Expedited U.S. Molgradex Development Strategy Ongoing IMPALA Study to be Expanded to Serve as Global Pivotal Study for Registration PR Newswire
08.05.17 - PR Newswire
Savara Announces Issuance Of U.S. Composition Of Matter Patent Covering AeroVanc
Savara Announces Issuance Of U.S. Composition Of Matter Patent Covering AeroVanc PR Newswire
01.05.17 - PR Newswire
Savara Secures $15 Million Loan And Security Agreement With Silicon Valley Bank
Savara Secures $15 Million Loan And Security Agreement With Silicon Valley Bank PR Newswire
28.04.17 - PR Newswire
Savara Announces Closing Of Merger With Mast Therapeutics
Savara Announces Closing Of Merger With Mast Therapeutics Commences Trading on Nasdaq Capital Market on April 28, 2017 Under Ticker Symbol "SVRA" Conference Call ...

Newssuche

Videos

newspaper
10:40 Uhr 0,00%
Technical Trading: 79,2 Trefferquote bei diesem Trade
S&P 500 Short Typ: Turbo Open End WKN: JK39CB Hebel: 5,28 Laufzeit: OpenEnd Einstieg: Market ... Mehr »